3 Power Transmission EPC Company, Branded Pharmaceuticals Company and Data Analytics Firm Stocks With a Strong Future Roadmap: Kalpataru Projects International, Torrent Pharmaceuticals and Latent View Analytics

Power EPC, branded medicine and analytics stocks let investors follow companies that serve a growing part of the Indian economy. Kalpataru Projects International, Torrent Pharmaceuticals and Latent View Analytics cover a power transmission EPC company, a branded pharmaceuticals company and a data analytics firm.

This list covers three power EPC, branded medicine and analytics stocks with complete current figures: Kalpataru Projects International, Torrent Pharmaceuticals and Latent View Analytics. Every figure comes from the latest reported financials and the 11 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Power EPC, Branded Medicine and Analytics Stocks?

Power EPC, branded medicine and analytics stocks are listed companies that build power transmission lines, pipelines and railway projects, develop and sell branded medicines for heart, brain and stomach care, and provide data and analytics services to global firms. Their earnings depend on project awards, prescription demand and client data budgets.

Power EPC, Branded Medicine and Analytics Stocks at a Glance

On valuation, Kalpataru Projects International trades at a P/E below the industry P/E, while Torrent Pharmaceuticals and Latent View Analytics trade above it, which reflects the growth the market already expects. Readers comparing power EPC, branded medicine and analytics stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in power EPC, branded medicine and analytics stocks can use the coming numbers to test whether growth is holding.

Why Do Power EPC, Branded Medicine and Analytics Stocks Have a Strong Roadmap in India?

Power EPC, branded medicine and analytics stocks have a strong roadmap in India because heavy grid and infrastructure spending, steady demand for branded medicines and wider use of data by firms keep widening the market for these companies.

• Power EPC. Grids and railways need large projects.
• Branded medicines. Doctors prescribe trusted chronic care brands.
• Analytics. Firms turn data into better decisions.

Why Kalpataru Projects International Features Among These Power EPC, Branded Medicine and Analytics Stocks

Among the power EPC, branded medicine and analytics stocks on this list, Kalpataru Projects International is an engineering and construction company that builds power transmission lines, railways, buildings, water pipelines and oil and gas infrastructure in India and abroad.

The company has a return on equity of 13.4%, a debt to equity ratio of 0.46 and a market capitalisation of Rs 22,241 crore. The stock trades at a P/E of 19.7, below the industry P/E of 22.3.

Revenue rose from Rs 14,866 crore in FY22 to Rs 27,248 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 535 crore in FY22 to Rs 1,031 crore in FY26, which works out to a compound annual growth rate of 17.8%. In the June 2026 quarter, revenue grew 4.8% year on year to Rs 6,485 crore, while net profit rose 45.9% to Rs 312 crore.

Roadmap: The company is winning larger projects across transmission, railways and urban infrastructure, and it is growing overseas. A diverse order book supports steady execution.

What to watch: Track order book growth, international contracts and working capital discipline.

Why Torrent Pharmaceuticals Features Among These Power EPC, Branded Medicine and Analytics Stocks

Among the transmission builder, prescription drug and data shares on this list, Torrent Pharmaceuticals is an Ahmedabad-based pharma company that leads in cardiovascular, central nervous system and gastro-intestinal therapies in India, with a growing presence in Brazil, Germany and the United States.

Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%.

In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0.

Roadmap: The company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.

What to watch: Watch the integration of newly acquired brands and the progress of margin improvement in the enlarged business.

Why Latent View Analytics Features Among These Power EPC, Branded Medicine and Analytics Stocks

Among the three companies on this list, Latent View Analytics, headquartered in Chennai, provides data analytics, engineering and artificial intelligence services to technology, consumer and financial clients worldwide.

In the June 2026 quarter, revenue grew 18.8% year on year to Rs 308 crore. Revenue rose from Rs 429 crore in FY22 to Rs 1,136 crore in FY26, a compound annual growth rate of 27.6%.

Net profit grew from Rs 130 crore in FY22 to Rs 202 crore in FY26, which works out to a compound annual growth rate of 11.8%. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 4,968 crore. The stock trades at a P/E of 25.0, above the industry P/E of 17.5.

Roadmap: Enterprises are investing in analytics and artificial intelligence, which feeds demand for data services. The company is widening its client list and scaling large accounts with a consulting and engineering model.

What to watch: Follow client additions and the growth of large accounts.

Kalpataru Projects International vs Torrent Pharmaceuticals vs Latent View Analytics on Key Financials

The table below sets the three power EPC, branded medicine and analytics stocks side by side on revenue, profit and margin, using reported figures.

Torrent Pharmaceuticals posts the highest return on equity in this group at 25.5%. Kalpataru Projects International has the largest FY26 revenue at Rs 27,248 crore, and Latent View Analytics shows the fastest revenue growth with a 27.6% compound annual rate. A useful habit with power EPC, branded medicine and analytics stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several line contractor, pharma brand and analytics services stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Power EPC, Branded Medicine and Analytics Stocks

Every theme carries risks that deserve a check before any decision. For these power EPC, branded medicine and analytics stocks, the main points are: Long-term transmission builder, prescription drug and data shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Order timing. Project awards can shift between periods.
• Pricing pressure. Generic prices can change by market.
• Client budgets. Spending can vary with global conditions.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter power EPC, branded medicine and analytics stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Power EPC, Branded Medicine and Analytics Stocks

Power EPC, branded medicine and analytics stocks reward investors who follow demand trends, order books and margins together. Kalpataru Projects International, Torrent Pharmaceuticals and Latent View Analytics each have a clear plan to grow. Based on the 11 November 2026 close, Kalpataru Projects International trades at Rs 1,354.4, Torrent Pharmaceuticals at Rs 4,761 and Latent View Analytics at Rs 210.98. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these power EPC, branded medicine and analytics stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track power EPC, branded medicine and analytics stocks, set price alerts and get research-backed stock ideas.

What are power EPC, branded medicine and analytics stocks?

Ans. Power EPC, branded medicine and analytics stocks are listed companies that build power transmission lines, pipelines and railway projects, develop and sell branded medicines for heart, brain and stomach care, and provide data and analytics services to global firms. Their earnings depend on project awards, prescription demand and client data budgets. This list looks at three of them, Kalpataru Projects International, Torrent Pharmaceuticals and Latent View Analytics, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.

Which power EPC, branded medicine and analytics stocks are covered in this list?

Ans. This list covers Kalpataru Projects International, Torrent Pharmaceuticals and Latent View Analytics. Based on the 11 November 2026 close, Kalpataru Projects International traded at Rs 1,354.4, Torrent Pharmaceuticals at Rs 4,761 and Latent View Analytics at Rs 210.98. Their return on equity ranges from 11.3% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.4% to 27.6%.

Why do power EPC, branded medicine and analytics stocks have a strong future roadmap in India?

Ans. Power EPC, branded medicine and analytics stocks have a strong roadmap in India because heavy grid and infrastructure spending, steady demand for branded medicines and wider use of data by firms keep widening the market for these companies. The main drivers are as follows. Power EPC. Grids and railways need large projects. Branded medicines. Doctors prescribe trusted chronic care brands. Analytics. Firms turn data into better decisions. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Kalpataru Projects International performed financially?

Ans. Revenue rose from Rs 14,866 crore in FY22 to Rs 27,248 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 535 crore in FY22 to Rs 1,031 crore in FY26, which works out to a compound annual growth rate of 17.8%. In the June 2026 quarter, revenue grew 4.8% year on year to Rs 6,485 crore, while net profit rose 45.9% to Rs 312 crore. The company has a return on equity of 13.4%, a debt to equity ratio of 0.46 and a market capitalisation of Rs 22,241 crore. The stock trades at a P/E of 19.7, below the industry P/E of 22.3. Looking ahead, the company is winning larger projects across transmission, railways and urban infrastructure, and it is growing overseas. A diverse order book supports steady execution.

How has Torrent Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.

How has Latent View Analytics performed financially?

Ans. Revenue rose from Rs 429 crore in FY22 to Rs 1,136 crore in FY26, a compound annual growth rate of 27.6%. Net profit grew from Rs 130 crore in FY22 to Rs 202 crore in FY26, which works out to a compound annual growth rate of 11.8%. In the June 2026 quarter, revenue grew 18.8% year on year to Rs 308 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 4,968 crore. The stock trades at a P/E of 25.0, above the industry P/E of 17.5. Looking ahead, enterprises are investing in analytics and artificial intelligence, which feeds demand for data services. The company is widening its client list and scaling large accounts with a consulting and engineering model.

What risks should investors check before buying power EPC, branded medicine and analytics stocks?

Ans. Investors should check a few risks before buying power EPC, branded medicine and analytics stocks. Order timing. Project awards can shift between periods. Pricing pressure. Generic prices can change by market. Client budgets. Spending can vary with global conditions. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of power EPC, branded medicine and analytics stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.